This content is from: Patents

Brexit: UK pharma fears international IP exhaustion scheme

Pharma in-house counsel say an international IP exhaustion framework could undercut the UK drugs market and create shortages in other parts of the world

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial